NCT02742623已完成不适用
COSIMO Cancer Associated Thrombosis - Patient Reported Outcomes With Rivaroxaban. A Non-interventional Study on Patients Changing to Xarelto® for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Patients With Active Cancer.
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 528
- 主要终点
- Treatment satisfaction burden score (ACTS)
研究概览
简要总结
This study aims to collect patient reported outcomes and assess treatment satisfaction in active cancer patients treated with rivaroxaban for VTE (venous thromboembolism).
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult female and male patients with active cancer other than fully treated basal-cell or squamous-cell carcinoma of the skin (active cancer defined as the diagnosis or treatment of cancer in the previous < 6 months or recurrent or metastatic cancer)
- •Patients that have been treated with standard of care anticoagulation (Low Molecular Weight Heparin / Vitamin K Antagonist) for treatment of DVT and/ or PE (index VTE event) and/ or prevention of recurrent DVT and PE for at least 4 weeks prior to inclusion in the study
- •Patients for whom the decision was made to start rivaroxaban for treatment of DVT and/ or PE and/ or prevention of recurrent DVT and PE
- •Patients with Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2
- •Patients who are willing to participate in this study (signed informed consent)
- •Patients who are available for follow-up with a life expectancy >6 months
排除标准
- •The contra-indications according to the local marketing authorization must be considered
- •Patients who developed an index VTE event despite chronic anticoagulant therapy
- •Patients receiving apixaban, edoxaban or dabigatran or any investigational drug as the initial therapy for the index VTE event
- •Patients participating in an investigational program with interventions outside of routine clinical practice with exception of oncology investigational trials
研究组 & 干预措施
Rivaroxaban
Female and male patients with active cancer and treated with rivaroxaban after a diagnosis of DVT/ and/or PE
干预措施: Rivaroxaban (Xarelto, BAY 59-7939) (Drug)
结局指标
主要结局
Treatment satisfaction burden score (ACTS)
时间窗: At 4 weeks
Patient reported treatment satisfaction will be assessed with regard to the Anti-Clot Treatment Scale (ACTS) burden score for the use of rivaroxaban for treatment of acute deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in patients with active cancer changing to this therapy.
次要结局
- Type of index VTE (venous thromboembolism) event(At baseline)
- Preferences regarding the attributes of the anticoagulation medication options LMWH, VKA, rivaroxaban using DCE survey(Between 4 weeks and 3 months)
- Change of ACTS score over time(At 3 months and 6 months)
- Patient's quality of life using the FACIT-Fatigue questionnaire(Up to 6 months)
- Type (trade name) of initial anticoagulation treatment(At baseline)
- Date of index VTE event(At baseline)
- Duration of initial anticoagulation treatment(At baseline)
- Reason for drug switch to rivaroxaban(At baseline)
- Planned duration of anticoagulation with rivaroxaban(At baseline)
- Actual duration of anticoagulation with rivaroxaban(Up to 6 months)
- Dosage of rivaroxaban(Up to 6 months)
- Reason for any potential dose adjustments during course of treatment with rivaroxaban(Up to 6 months)
- Reasons for any switch from rivaroxaban treatment(Up to 6 months)
- Reasons for permanent cessation of rivaroxaban treatment(Up to 6 months)
- TNM Staging (Clinical characteristics of cancer disease)(At baseline)
- Primary site of cancer (Clinical characteristics of cancer disease)(At baseline)
- Type of bleeding events(Up to 6 months)
- Number of bleeding events(Up to 6 months)
- Type of thromboembolic events(Up to 6 months)
- Number of thromboembolic events(Up to 6 months)
研究者
相似试验
终止
不适用
Patient Reported Outcome Measures (PROMs) With TrabectedinSarcomaLeiomyosarcomaLiposarcomaNCT03959033University of Leeds7
已完成
不适用
Anticoagulant Therapy and 28-days Mortality in Critically Ill COVID-19 PatientsCovid-19Thromboembolic EventsBleedingNCT04412304Karolinska Institutet166
已完成
不适用
Symptom Experience and Self-management After Haematopoietic Stem Cell TransplantationHematologic NeoplasmsNCT01275534University Hospital, Basel, Switzerland375
已完成
不适用
A Study to Gather Information About Rivaroxaban in Patients in Sweden With Cancer Who Also Have Thrombosis (OSCAR-SE)Treatment of Venous Thromboembolism in Cancer PatientsNCT05150938Bayer5,737
已完成
不适用
Study of Patient Satisfaction With the Cancer Clinical Trial ExperienceCancerNCT00768976Summa Health System100